. | Original FAB classification . | . | . | ||
|---|---|---|---|---|---|
| WHO classification . | RA, n = 24 . | RARS, n = 22 . | RAEB, n = 18 . | ||
| RA | 3 | 0 | 0 | ||
| RARS | 0 | 9 | 0 | ||
| RAEB-1 | 0 | 0 | 12 | ||
| RAEB-2 | 0 | 0 | 4 | ||
| RCMD | 13 | 0 | 0 | ||
| RCMD/RS | 0 | 11 | 0 | ||
| 5q-syndrome | 7 | 1 | 0 | ||
| Unclassified | 1 | 1 | 2 | ||
. | Original FAB classification . | . | . | ||
|---|---|---|---|---|---|
| WHO classification . | RA, n = 24 . | RARS, n = 22 . | RAEB, n = 18 . | ||
| RA | 3 | 0 | 0 | ||
| RARS | 0 | 9 | 0 | ||
| RAEB-1 | 0 | 0 | 12 | ||
| RAEB-2 | 0 | 0 | 4 | ||
| RCMD | 13 | 0 | 0 | ||
| RCMD/RS | 0 | 11 | 0 | ||
| 5q-syndrome | 7 | 1 | 0 | ||
| Unclassified | 1 | 1 | 2 | ||
Included in clinical growth factor trials; see Hellström-Lindberg et al10 and Tehranchi et al.26
Patients were reclassified according to FAB and then according to WHO. The table shows the reclassified FAB diagnoses. Four cases were difficult to reclassify to FAB and could not be reclassified according to WHO guidelines (ie, there was no megakaryopoiesis available for evaluation). These patients are listed under their original FAB diagnosis.